Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Coming to you well over a month late, we still want to acknowledge the many comings and goings we saw in the biotech industry in April. Stay tuned for a combined May-June edition to get us back on ...

Wake up with Oxfordshire's latest news, great music and conversation with Sophie.